164 related articles for article (PubMed ID: 27631562)
1. CE/BZA effects on bone and quality of life in European postmenopausal women: a pooled analysis.
Hadji P; Ryan KA; Yu CR; Mirkin S; Komm BS
Climacteric; 2016 Oct; 19(5):482-7. PubMed ID: 27631562
[TBL] [Abstract][Full Text] [Related]
2. Changes in bone mineral density are correlated with bone markers and reductions in hot flush severity in postmenopausal women treated with bazedoxifene/conjugated estrogens.
Gallagher JC; Shi H; Mirkin S; Chines AA
Menopause; 2013 Nov; 20(11):1126-32. PubMed ID: 23632659
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials.
Pinkerton JV; Abraham L; Bushmakin AG; Cappelleri JC; Racketa J; Shi H; Chines AA; Mirkin S
J Womens Health (Larchmt); 2014 Jan; 23(1):18-28. PubMed ID: 24206058
[TBL] [Abstract][Full Text] [Related]
4. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women.
Mirkin S; Komm BS; Pan K; Chines AA
Climacteric; 2013 Jun; 16(3):338-46. PubMed ID: 23038989
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.
Lindsay R; Gallagher JC; Kagan R; Pickar JH; Constantine G
Fertil Steril; 2009 Sep; 92(3):1045-1052. PubMed ID: 19635616
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the measurement model and clinically important differences for menopause-specific quality of life associated with bazedoxifene/conjugated estrogens.
Bushmakin AG; Abraham L; Pinkerton JV; Cappelleri JC; Mirkin S
Menopause; 2014 Aug; 21(8):815-22. PubMed ID: 24378765
[TBL] [Abstract][Full Text] [Related]
7. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.
Pinkerton JV; Utian WH; Constantine GD; Olivier S; Pickar JH
Menopause; 2009; 16(6):1116-24. PubMed ID: 19546826
[TBL] [Abstract][Full Text] [Related]
8. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women.
Utian W; Yu H; Bobula J; Mirkin S; Olivier S; Pickar JH
Maturitas; 2009 Aug; 63(4):329-35. PubMed ID: 19647382
[TBL] [Abstract][Full Text] [Related]
9. Tissue-selective estrogen complexes for postmenopausal women.
Mirkin S; Komm BS
Maturitas; 2013 Nov; 76(3):213-20. PubMed ID: 23849704
[TBL] [Abstract][Full Text] [Related]
10. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
Pinkerton JV; Pickar JH; Racketa J; Mirkin S
Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444
[TBL] [Abstract][Full Text] [Related]
11. Sleep parameters and health-related quality of life with bazedoxifene/conjugated estrogens: a randomized trial.
Pinkerton JV; Pan K; Abraham L; Racketa J; Ryan KA; Chines AA; Mirkin S
Menopause; 2014 Mar; 21(3):252-9. PubMed ID: 23942245
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of bazedoxifene in postmenopausal women by baseline kidney function status.
Adami S; Palacios S; Rizzoli R; Levine AB; Sutradhar S; Chines AA
Climacteric; 2014 Jun; 17(3):273-84. PubMed ID: 23937421
[TBL] [Abstract][Full Text] [Related]
13. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
Bachmann G; Bobula J; Mirkin S
Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
[TBL] [Abstract][Full Text] [Related]
14. Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE).
Lindsay R
Osteoporos Int; 2011 Feb; 22(2):447-51. PubMed ID: 21069294
[TBL] [Abstract][Full Text] [Related]
15. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.
Pinkerton JV; Harvey JA; Lindsay R; Pan K; Chines AA; Mirkin S; Archer DF;
J Clin Endocrinol Metab; 2014 Feb; 99(2):E189-98. PubMed ID: 24438370
[TBL] [Abstract][Full Text] [Related]
16. Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause.
Tella SH; Gallagher JC
Expert Opin Pharmacother; 2013 Dec; 14(17):2407-20. PubMed ID: 24093499
[TBL] [Abstract][Full Text] [Related]
17. Selective estrogen modulators in menopause.
Gambacciani M
Minerva Ginecol; 2013 Dec; 65(6):621-30. PubMed ID: 24346250
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the direct and indirect effects of bazedoxifene/conjugated estrogens on sleep disturbance using mediation modeling.
Pinkerton JV; Bushmakin AG; Racketa J; Cappelleri JC; Chines AA; Mirkin S
Menopause; 2014 Mar; 21(3):243-51. PubMed ID: 23899830
[TBL] [Abstract][Full Text] [Related]
19. Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women.
Yu H; Racketa J; Chines AA; Mirkin S
Climacteric; 2013 Apr; 16(2):252-7. PubMed ID: 23035721
[TBL] [Abstract][Full Text] [Related]
20. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.
Pickar JH; Mirkin S
Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
